Skip to main content
Top
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | Campylobacter | Case report

Relapsing cellulitis associated with Campylobacter coli bacteremia in a Good’s syndrome patient: a case report

Authors: Lei Jiang, Jia Gao, Pu Wang, Yuliang Liu

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Background

Good’s syndrome (GS) is characterized by immunodeficiency, and patients diagnosed with GS are susceptible to infection or even bacteremia, which is the most evident complication. Campylobacter coli (C. coli) rarely causes bacteremia or extraintestinal infection. We report herein a case with GS in which right leg cellulitis associated with C. coli bacteremia occurred three times over one and a half years.

Case presentation

A 41-year-old Chinese male with GS was diagnosed with C. coli infection. He presented with swelling and redness of right lower leg and developed bacteremia due to C. coli repeatedly. Bacteremia was confirmed by bacteriological examination. Adding long-term oral antibiotic treatment with amoxicillin/clavulanate potassium and gentamicin following intravenous meropenem and amikacin was very effective. The blood cultures became negative and the patient has been free from any symptoms encountered for more than one year without relapse of bacteremia.

Conclusions

Patients with GS and their physicians should carefully consider the antibacterial treatment options against C. coli bacteremia. Combined anti-infective therapy involving aminoglycoside is preferred in the treatment of C. coli bacteremia in GS patients.
Literature
1.
go back to reference Kabir A, Alizadehfar R, Tsoukas CM. Good’s syndrome: time to move on from reviewing the past. Front Immunol. 2021;12:815710.CrossRef Kabir A, Alizadehfar R, Tsoukas CM. Good’s syndrome: time to move on from reviewing the past. Front Immunol. 2021;12:815710.CrossRef
2.
go back to reference Zaman M, Huissoon A, Buckland M, et al. Clinical and laboratory features of seventy-eight UK patients with Good’s syndrome (thymoma and hypogammaglobulinaemia). Clin Exp Immunol. 2019;195(1):132–8.CrossRef Zaman M, Huissoon A, Buckland M, et al. Clinical and laboratory features of seventy-eight UK patients with Good’s syndrome (thymoma and hypogammaglobulinaemia). Clin Exp Immunol. 2019;195(1):132–8.CrossRef
3.
go back to reference Shi Y, Wang C. When the good syndrome goes bad: a systematic literature review. Front Immunol. 2021;12:679556.CrossRef Shi Y, Wang C. When the good syndrome goes bad: a systematic literature review. Front Immunol. 2021;12:679556.CrossRef
4.
go back to reference Nielsen H, Hansen KK, Gradel KO, et al. Bacteraemia as a result of Campylobacter species: a population-based study of epidemiology and clinical risk factors. Clin Microbiol Infect. 2010;16(1):57–61.CrossRef Nielsen H, Hansen KK, Gradel KO, et al. Bacteraemia as a result of Campylobacter species: a population-based study of epidemiology and clinical risk factors. Clin Microbiol Infect. 2010;16(1):57–61.CrossRef
5.
go back to reference Pereira L, Sampaio S, Tavares I, Bustorff M, Pestana M. Bacteremia due to Campylobacter in renal transplantation: a case report and review of literature. Transpl Infect Dis. 2014;16(6):1007–11.CrossRef Pereira L, Sampaio S, Tavares I, Bustorff M, Pestana M. Bacteremia due to Campylobacter in renal transplantation: a case report and review of literature. Transpl Infect Dis. 2014;16(6):1007–11.CrossRef
6.
go back to reference Okada H, Kitazawa T, Harada S, et al. Combined treatment with oral kanamycin and parenteral antibiotics for a case of persistent bacteremia and intestinal carriage with Campylobacter coli. Intern Med. 2008;47(14):1363–6.CrossRef Okada H, Kitazawa T, Harada S, et al. Combined treatment with oral kanamycin and parenteral antibiotics for a case of persistent bacteremia and intestinal carriage with Campylobacter coli. Intern Med. 2008;47(14):1363–6.CrossRef
7.
go back to reference Mirzaei R, Mohammadzadeh R, Alikhani MY, et al. The biofilm-associated bacterial infections unrelated to indwelling devices. IUBMB Life. 2020;72(7):1271–85.CrossRef Mirzaei R, Mohammadzadeh R, Alikhani MY, et al. The biofilm-associated bacterial infections unrelated to indwelling devices. IUBMB Life. 2020;72(7):1271–85.CrossRef
8.
go back to reference Jamal M, Ahmad W, Andleeb S, et al. Bacterial biofilm and associated infections. J Chin Med Assoc. 2018;81(1):7–11.CrossRef Jamal M, Ahmad W, Andleeb S, et al. Bacterial biofilm and associated infections. J Chin Med Assoc. 2018;81(1):7–11.CrossRef
9.
go back to reference Ohadi E, Bakhshi B, Kalani BS, Talebi M, Irajian G. Transcriptome analysis of biofilm formation under aerobic and microaerobic conditions in clinical isolates of Campylobacter spp. Res Vet Sci. 2021;142:24–30.CrossRef Ohadi E, Bakhshi B, Kalani BS, Talebi M, Irajian G. Transcriptome analysis of biofilm formation under aerobic and microaerobic conditions in clinical isolates of Campylobacter spp. Res Vet Sci. 2021;142:24–30.CrossRef
10.
go back to reference Wooldridge KG, Ketley JM. Campylobacter-host cell interactions. Trends Microbiol. 1997;5(3):96–102.CrossRef Wooldridge KG, Ketley JM. Campylobacter-host cell interactions. Trends Microbiol. 1997;5(3):96–102.CrossRef
11.
go back to reference Janssen R, Krogfelt KA, Cawthraw SA, van Pelt W, Wagenaar JA, Owen RJ. Host-pathogen interactions in Campylobacter infections: the host perspective. Clin Microbiol Rev. 2008;21(3):505–18.CrossRef Janssen R, Krogfelt KA, Cawthraw SA, van Pelt W, Wagenaar JA, Owen RJ. Host-pathogen interactions in Campylobacter infections: the host perspective. Clin Microbiol Rev. 2008;21(3):505–18.CrossRef
12.
go back to reference Hagiya H, Kimura K, Nishi I, et al. Emergence of carbapenem non-susceptible Campylobacter coli after long-term treatment against recurrent bacteremia in a patient with X-linked agammaglobulinemia. Intern Med. 2018;57(14):2077–80.CrossRef Hagiya H, Kimura K, Nishi I, et al. Emergence of carbapenem non-susceptible Campylobacter coli after long-term treatment against recurrent bacteremia in a patient with X-linked agammaglobulinemia. Intern Med. 2018;57(14):2077–80.CrossRef
13.
go back to reference Ariganello P, Angelino G, Scarselli A, et al. Relapsing Campylobacter jejuni systemic infections in a child with X-Linked Agammaglobulinemia. Case Rep Pediatr. 2013;2013:735108.PubMedPubMedCentral Ariganello P, Angelino G, Scarselli A, et al. Relapsing Campylobacter jejuni systemic infections in a child with X-Linked Agammaglobulinemia. Case Rep Pediatr. 2013;2013:735108.PubMedPubMedCentral
14.
go back to reference Tokuda K, Nishi J, Miyanohara H, et al. Relapsing cellulitis associated with Campylobacter coli bacteremia in an agammaglobulinemic patient. Pediatr Infect Dis J. 2004;23(6):577–9.CrossRef Tokuda K, Nishi J, Miyanohara H, et al. Relapsing cellulitis associated with Campylobacter coli bacteremia in an agammaglobulinemic patient. Pediatr Infect Dis J. 2004;23(6):577–9.CrossRef
15.
go back to reference Monselise A, Blickstein D, Ostfeld I, Segal R, Weinberger M. A case of cellulitis complicating Campylobacter jejuni subspecies jejuni bacteremia and review of the literature. Eur J Clin Microbiol Infect Dis. 2004;23(9):718–21.CrossRef Monselise A, Blickstein D, Ostfeld I, Segal R, Weinberger M. A case of cellulitis complicating Campylobacter jejuni subspecies jejuni bacteremia and review of the literature. Eur J Clin Microbiol Infect Dis. 2004;23(9):718–21.CrossRef
16.
go back to reference Gibreel A, Taylor DE. Macrolide resistance in Campylobacter jejuni and Campylobacter coli. J Antimicrob Chemother. 2006;58(2):243–55.CrossRef Gibreel A, Taylor DE. Macrolide resistance in Campylobacter jejuni and Campylobacter coli. J Antimicrob Chemother. 2006;58(2):243–55.CrossRef
17.
go back to reference Jang YS, Mosolygo T. Inhibition of bacterial biofilm formation by phytotherapeutics with focus on overcoming antimicrobial resistance. Curr Pharm Des. 2020;26(24):2807–16.CrossRef Jang YS, Mosolygo T. Inhibition of bacterial biofilm formation by phytotherapeutics with focus on overcoming antimicrobial resistance. Curr Pharm Des. 2020;26(24):2807–16.CrossRef
18.
go back to reference Moore JE, Barton MD, Blair IS, et al. The epidemiology of antibiotic resistance in Campylobacter. Microbes Infect. 2006;8(7):1955–66.CrossRef Moore JE, Barton MD, Blair IS, et al. The epidemiology of antibiotic resistance in Campylobacter. Microbes Infect. 2006;8(7):1955–66.CrossRef
19.
go back to reference Najjar I, Paluca F, Loukidis K, Tarr PE. Recurrent Campylobacter enteritis in patients with hypogammaglobulinemia: review of the literature. J Clin Med. 2020;9(2):553.CrossRef Najjar I, Paluca F, Loukidis K, Tarr PE. Recurrent Campylobacter enteritis in patients with hypogammaglobulinemia: review of the literature. J Clin Med. 2020;9(2):553.CrossRef
Metadata
Title
Relapsing cellulitis associated with Campylobacter coli bacteremia in a Good’s syndrome patient: a case report
Authors
Lei Jiang
Jia Gao
Pu Wang
Yuliang Liu
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07324-3

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.